IceCure Medical (ICCM) announced it received a Notice of Allowance for a patent from the China National Intellectual Property Administration for its invention titled “Cryogen Flow Control” which relates to its next-generation XSense cryoablation system and probes. A patent for this invention has been granted in Japan and is currently pending approval in the European Union, the U.S., and other major markets.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure Medical Announces Special General Meeting for Key Votes
- Promising Growth and Strategic Expansion Justify Buy Rating for Icecure Medical
- IceCure Medical Reports Q3 2025 Financial Results
- IceCure Medical’s Earnings Call Highlights Growth Potential
- IceCure Medical Gains FDA Approval for ProSense® in Breast Cancer Treatment